SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001213900-26-057939
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026057939/ea0290954-s1_synergy.htm

Chunk 4 of 16
Word Count: 1498
Character Count: 10044

Document Content:

our current retail partners, such as the addition of FOCUSfactor RTDs and vision products to these retail partners and other channels. Additionally, the international footprint of certain of our various retail partners facilitates our geographic expansion plans. Scalable and Flexible Asset-Light Model to Support Growth Our focus is on brand management, marketing, product development and distribution, and we utilize contract manufacturing partners in order to produce our various brand offerings. The use of third-party manufacturing partners allows us to scale quickly, as we ensure that our partners have sufficient capacity to meet our demand needs. We also maintain multiple relationships with different contract manufacturers, ensuring diversification of our manufacturing base and reducing the likelihood of supply bottlenecks or deficits that could potentially slow our growth. Our Growth Strategy We intend to drive growth and increased profitability in our business through these key elements of our strategy: Broaden Media Advertising Strategy

We have experienced significant
acceleration in sales growth for the FOCUSfactor brand as a result of our television advertising in prior years. We launched a national
advertising campaign in August 2020, which aired on major news and entertainment networks such as Fox News, CNN, MSNBC, TLC, and TNT,
targeting adults 45 years of age and older. We anticipate a coordinated expansion of our advertising strategy during 2026, as we focus
on pushing additional SKUs within our retail sales partner network to continue to build brand awareness and increase reach for FOCUSfactor.
We also plan to continue to invest in online marketing to promote all of our brands, including social media and influencer driven marketing.
We have also experienced significant growth through our increased distribution, which we continue to drive forward.

Acquire Brands which Complement Our Existing
Portfolio

We will continue to evaluate
acquisition opportunities that we believe fit well within our brand portfolio and create value for our stockholders, such as further retail
expansion in nutraceuticals and market expansion in health and beauty. In spite of historical capital constraints, our opportunistic approach
to acquisitions has resulted in a successful track record of identifying promising targets that align with our overall brand strategy
in the health, beauty and lifestyle segments.

Partner with Additional Leading Retailers
to Expand the Reach of Our Products

Based on the success of our
products with our established leading retail partners, we believe that we are well positioned to add new retailers that will enhance our
distribution footprint. We believe we have expansion opportunities with food retailers, including those focused on health foods.

Diversify Our Geographic Presence through
Entry into New Markets

We seek to accelerate our sales
growth by expanding and further diversifying our geographic footprint. For the year ended December 31, 2025, substantially all of our
revenue was generated within North America. Our goal is to increase our revenues generated from new markets. As we target new international
markets, our strategy is to develop highly competitive and differentiated products that are produced in-country for ease of entry, with
support from our regulatory group and an in-country regulatory consultant to help expedite the approval process. We entered the Mexico
market in the fourth quarter of 2025 and plan to enter Taiwan and Asia in 2026, initially with FOCUSfactor, followed by Flat Tummy. We
then plan to expand our brands into Australia (where we have Therapeutic Goods Administration (“TGA”) approval for our FOCUSfactor
products). In addition, we are developing our marketing plans in compliance with applicable law and are initiating retailer meetings as
we seek to gain distribution across these new retail markets.

Use Innovative Strategies to Boost Consumer
Engagement

We have made investments in
promoting an app for Flat Tummy and view this as a key aspect of growing our customer base and maintaining high levels of engagement.
We have also focused on developing our social media presence, in particular through Instagram, in order to foster and grow our relationship
with customers. Our brands appeal to both specific consumer needs as well as lifestyle choices and we seek to deepen our understanding
of our customers and boost recognition of our brands through increased engagement.

Continue to Develop and Expand Our Current
Brands

Our plan is to further develop
and expand our brands by reaching a broader set of customers through advertising and product expansion. More specifically, we look to
develop new products for our brands to satisfy the various customer segment opportunities (i.e., baby boomers, millennials, etc.) and
satisfy various consumer needs as they relate to new and improved formulations, expanded and improved product benefits, alternative delivery
formats and sizes. As we increase the product line-up behind our brands, we leverage our current retail distribution network by expanding
our presence as well as adding incremental distribution with new retail partners. With a broader brand presence, we believe our advertising
becomes even more efficient at driving sales velocity.

This is evidenced by our expanded
FOCUSfactor product line, including focus and energy RTD and liquid shots that are marketed to a younger adult audience. In 2023, we successfully
launched an RTD pilot program in the United States through a major retailer. Additionally, in the second quarter of 2024, we launched
three core FOCUSfactor focus and energy RTD products in Canada. In the first quarter of 2025, we introduced new complementary products
to the Flat Tummy line-up, including new protein shakes, GLP-1 support products and pre-workout powders. In the fourth quarter of 2025,
we introduced FOCUSfactor to Mexico.

Marketing and Sales

Our targeted, consumer-driven marketing
strategy has been key to building our brands and driving revenue growth. We manage dedicated marketing strategies for each of our brands
in order to build deep connections with our customers.

FOCUSfactor.    Our
marketing strategy for FOCUSfactor is primarily focused on increased distribution and advertising campaigns that appeal to the demographics
of our wellness focused customer base. For the year ended December 31, 2025, FOCUSfactor net revenue decreased 10% year-over-year,
to $27.8 million, primarily due to the rebranding and packaging upgrade we undertook. As our flagship brand, FOCUSfactor accounted
for 92% of our net revenue in the year ended December 31, 2025, compared with 88% in the year ended December 31, 2024.

Flat Tummy.    We
employ a primarily online and social media driven strategy for our Flat Tummy brand. The brand is focused primarily on women. We employ
campaigns to reach our core target segments through a mix of traditional online advertising as well as influencer-based marketing.
For the year ended December 31, 2025, Flat Tummy accounted for 8% of our net revenue, compared with 12% of our net revenue in the year
ended December 31, 2024.

Competition

The U.S. nutritional supplements
retail industry is a large and highly fragmented industry with few barriers to entry. We compete against other domestic and international
manufacturers, specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer companies,
and e-commerce companies. This market is highly sensitive to the introduction of new products, which may rapidly capture a significant
share of the market. Certain of our competitors may have significantly greater financial, technical and marketing resources than we do,
and may be able to adapt to changes in consumer preferences more quickly, devote greater resources to the marketing and sale of their
products, or generate greater brand recognition. In addition, our competitors may be more effective and efficient in introducing new products.

Although there are many competing
products on the market across our product categories, we believe that the FOCUSfactor brand is strengthened by an independent study to
support its claim of improving memory, concentration and focus. FOCUSfactor’s competitors include a wide range of products, from
targeted brain-enhancement supplements to indirect competitors such as energy drinks that claim to improve concentration. Our Flat Tummy
brand competes in well-established segments with a diverse range of competition both domestically and internationally.

Non-GAAP Financial Measures

We currently focus on EBITDA
to evaluate our business relationships and our resulting operating performance and financial position. EBITDA is defined as net income
plus interest expense, income tax expense, depreciation and amortization.

We believe that EBITDA, viewed
in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United States
(“U.S. GAAP”), provides useful information to investors.

Year Ended December 31, 2025 Year Ended December 31, 2024

Net income $	(12,341,208	) $	2,124,976

Interest income (15,065	) (1,523	)

Interest expense 5,919,742 4,105,198

Income tax expense 117,471 102,085

Depreciation and amortization 133,334 133,334

EBITDA $	(6,185,726	) $	6,464,070

EBITDA is considered a non-GAAP
financial measure. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definition of EBITDA might not
be comparable to similarly titled measures reported by other companies.

Summary Risk Factors

An investment in our common
stock involves a high degree of risk. You should carefully consider the risks summarized below. These risks are discussed more fully in
the section titled “Risk Factors” following this prospectus summary and under similar headings in the documents incorporated
by reference into this prospectus. These risks include, but are not limited to, the following: